GSK (GSK)
NYSE: GSK
· Real-Time Price · USD
39.22
0.09 (0.23%)
At close: Aug 14, 2025, 3:59 PM
39.30
0.20%
After-hours: Aug 14, 2025, 07:46 PM EDT
0.23% (1D)
| Bid | 38.65 |
| Market Cap | 79.08B |
| Revenue (ttm) | 31.63B |
| Net Income (ttm) | 3.42B |
| EPS (ttm) | 2.22 |
| PE Ratio (ttm) | 17.67 |
| Forward PE | 9.69 |
| Analyst | Hold |
| Ask | 39.95 |
| Volume | 2,485,215 |
| Avg. Volume (20D) | 5,139,037 |
| Open | 38.76 |
| Previous Close | 39.13 |
| Day's Range | 38.64 - 39.22 |
| 52-Week Range | 31.72 - 44.67 |
| Beta | 0.27 |
Analyst Forecast
According to 0 analyst ratings, the average rating for GSK stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsNext Earnings Release
GSK is scheduled to release its earnings on
Oct 29, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
2 weeks ago
+3.45%
GSK shares are trading higher after the company re...
Unlock content with
Pro Subscription
3 weeks ago
+2.73%
GSK shares are trading higher after the company announced an extension of the FDA review period for Blenrep in relapsed/refractory multiple myeloma, with a new PDUFA date set for October 23, 2025.
4 days ago · proactiveinvestors.co.uk
GSK opens higher after priority review for new gonorrhoea pillShares in GSK PLC (LSE:GSK, NYSE:GSK) opened higher following the US Food and Drug Administration's acceptance of gepotidacin for priority review as an oral treatment for uncomplicated urogenital gono...
1 week ago · proactiveinvestors.co.uk
GSK secures $370 million settlement and future royalties in CureVac mRNA patent disputeGSK PLC (LSE:GSK, NYSE:GSK) will receive an upfront payment of $370 million from CureVac, following a patent settlement involving BioNTech and Pfizer over messenger ribonucleic acid (mRNA) vaccine tec...
